IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The ...
Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that's working with Gilead's Kite unit.
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...
Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...
Tenpoint Therapeutics’ presbyopia drug showed “significant improvements” in near vision and reading speed in a Phase 3 trial. The biotech said the results keep it on track for an FDA filing in the ...
Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.
H1 acquires Ribbon Health to expand doctor-patient connections. Ribbon serves about 25M patients yearly; H1 aims to reach ...
Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback